Popular on Amzeal
- ProStrategix Proud To Announce Being Chosen as a Top Web Design Agency by DesignRush
- Romance Scams. Senior Women Hit the Hardest - Be Smarter Than Your Phone Cyber Security Podcast
- HLN Releases Open Source Vaccine Provider Agreement System
- You, Google, Microsoft, Facebook Should Use This New Tech For More Growth In The World
- New York State Small Business Owner Molly Bakewell Chamberlin Appointed to Washington, D.C.-Based NSBA Leadership and Technology Councils
- A Special New Spark Design Award Announced
- Business Owners Can Find System Flaws Before Cyber Criminals Do with the No-Cost Discovery Assessment from Infoaxis
- BrainKraft and career.pm Announce Product Launch Partnership
- Techspert Services IT Support is now available in Tampa, FL
- Daly joins Jigsaw24 in partner push
Similar on Amzeal
- Adare Biome™ Enters North American Distribution Through Stratum Nutrition® for LBiome™ Postbiotic
- Truthset and the ANA AIMM Release First of its Kind Multicultural Online Data Benchmarks
- Julia Hair Tax Refund Season Flash Sale Week With Buy Now Pay Later
- Liquid Core® Gum Company announces TDA Boulder Creative Director Jonathan Schoenberg has joined its Advisory Board
- myLAB Box Launches 16 New At-Home Tests, Offering Comprehensive Health Monitoring from the Comfort of Home
- Zilker Partners Acquires Growth Digital, Forming One-of-a-Kind Firm
- Tech Startup Mokusei Intelligence Announces the '$500 Press Challenge'
- ChartSpan Announces Partnership with Kentucky Hospital Association
- Mental Health Advocate Offers Hope to Millions with Book Detailing Trials and Triumphs on His Journey to Leading a Meaningful Life
- 2021 Marketing Excellence Awards—Call for Entries: Honoring the Best in B2B Services and Solutions Marketing
New reports from 83bar Patient Activation market research
Amzeal News/10406086
* Insights from recent market tests using its integrated digital health platform
* Highlights from seven important medical categories, to compare and contrast results from tests in a range of conditions
* Implications of findings for pharma brands, medical devices, and clinical trial recruitment to accelerate and improve patient journey management
* Highlights from seven important medical categories, to compare and contrast results from tests in a range of conditions
* Implications of findings for pharma brands, medical devices, and clinical trial recruitment to accelerate and improve patient journey management
AUSTIN, Texas - Amzeal -- 83bar Inc. has published a series of reports from its Patient Activation market research. The reports are now available with key findings and conclusions for seven important medical categories.
83bar generated the report data using its fully integrated digital health technology and clinical contact platform. The company has achieved significant results with its process for provider networks, commercial clients, and clinical trial sponsors. These reports demonstrate the value to accelerate and improve patient journey management.
According to Bob Baurys, CEO of 83bar, "We're advancing patient journey management as the next step from patient activation. This data enables us to identify patients willing to begin an assessment, engage in education, and then commit and sustain their patient journey. These market reports help us listen to how patients speak."
Alex Hilderbrand, vice president of patient activation & strategy at 83bar, directed the execution of the research, as well as the compilation of the data analysis. He says, "The response and form-fill rates are consistent across disease states. When we look at a marketing funnel, the number of patients you get at the top is about prevalence. But once you get past that key variable, the rates start looking similar across different patient groups. After people take our online survey and submit, the contact rates are almost always between 30% to 50%. We also find that the percentage who meet specific criteria and who are willing to move forward is also fairly similar across campaigns. We start seeing 20% to 35% of qualified patients want to move forward."
More on Amzeal News
Here are highlights from the reports.
More on Amzeal News
For more information and to download any of these reports, visit https://www.83bar.com/market-feasibility.
About 83bar Inc.
83bar Inc. headquartered in Austin, Texas manages the patient journey from symptom to solution. We empower patients with education to help self-champion and expedite a positive healthcare outcome. Our 4-part LENA (Locate, Evaluate, Navigate & Activate) system delivers ready-to-act patients to medical providers, on behalf of our medical device, medical diagnostics, and medical sciences partners. Over the last 5 years, we have completed over 1.5 million prospective patient conversations resulting in 100,000+ successful patient pathway outcomes across 20+ therapeutic areas and associated diseases. To find out how 83bar can help your medical device, medical diagnostic, or clinical trial, visit us at www.83bar.com.
83bar generated the report data using its fully integrated digital health technology and clinical contact platform. The company has achieved significant results with its process for provider networks, commercial clients, and clinical trial sponsors. These reports demonstrate the value to accelerate and improve patient journey management.
According to Bob Baurys, CEO of 83bar, "We're advancing patient journey management as the next step from patient activation. This data enables us to identify patients willing to begin an assessment, engage in education, and then commit and sustain their patient journey. These market reports help us listen to how patients speak."
Alex Hilderbrand, vice president of patient activation & strategy at 83bar, directed the execution of the research, as well as the compilation of the data analysis. He says, "The response and form-fill rates are consistent across disease states. When we look at a marketing funnel, the number of patients you get at the top is about prevalence. But once you get past that key variable, the rates start looking similar across different patient groups. After people take our online survey and submit, the contact rates are almost always between 30% to 50%. We also find that the percentage who meet specific criteria and who are willing to move forward is also fairly similar across campaigns. We start seeing 20% to 35% of qualified patients want to move forward."
More on Amzeal News
- Now Available at NeoMetrix Technologies, the NEW peel 2S
- ConvergeOne and Evolve IP Enter Strategic Hospitality Partnership
- Alliance Technologies Launches Alliance University
- Home2 Suites by Hilton Tucson Airport Celebrates Topping Off - Tucson's Newest Extended-Stay Hotel
- Truthset and the ANA AIMM Release First of its Kind Multicultural Online Data Benchmarks
Here are highlights from the reports.
- HIGH-INTENT TO PARTICIPATE IN COVID-19 STUDIES: In a test to recruit patients for coronavirus-related clinical trials and patient registries, the survey included people who had tested positive or who were symptomatic. In a five-day period, 315 respondents shared their symptoms, information, and interest in registries or trials related to COVID-19. The majority are interested in learning more about clinical trials and are motivated to participate.
- CAMPAIGN EFFECTIVENESS ACROSS KIDNEY DISEASE SPECTRUM; COMMON (DIABETIC NEPHROPATHY), TO RARE (FSGS AND IGA NEPHROPATHY): In campaigns for two kinds of kidney disease, information was collected from nearly 500 patients. In both tests, patients were identified who met enrollment criteria for clinical trials at rates higher than the industry average. In the rare disease feasibility test, 14% met the qualifying profile. Of those, 48% said they wanted to be contacted about clinical trials. In the diabetic nephropathy market test, approximately 20% were qualified and of those, 81% expressed interest to be contacted about trials.
- SIMILARITIES BETWEEN UROLOGICAL CONDITIONS AFFECTING MEN OR WOMEN (BPH AND UTI): In a market test in Benign Prostatic Hypertrophy, 83bar collected profile information from males, with more than 70% experiencing moderate to severe BPH symptoms, while fewer than one-third had a formal diagnosis. Among those treating their BPH symptoms, seven out of ten are not satisfied with the results. The majority of respondents are motivated to seek other options for a minimally invasive procedure. In a separate test in Urinary Tract Infection, 70% of women had a diagnosis, yet only 35% said they currently receive treatment. The majority report feeling very unhappy, and most are willing to receive a second opinion.
- CONTRAST BETWEEN PAINFUL CHRONIC CONDITIONS (GOUT AND FIBROIDS): In the market test in men with Gout, 83bar found more than 80% of men rated their pain severe or very severe, with only 25% having no doctor-directed care. In a test among women with fibroids, 75% reported pelvic/abdominal pain and 77% claimed a negative impact on daily life – but in contrast, 78% said they were not under a doctor's treatment.
More on Amzeal News
- Julia Hair Tax Refund Season Flash Sale Week With Buy Now Pay Later
- The Best Virgin Hair Vendors 2021
- ACS Lawyer In Brooklyn Announces Dismissal of OCFS Case
- Infosec's Choose Your Own Adventure® Security Awareness Games win Achievement of the Year in Video
- Liquid Core® Gum Company announces TDA Boulder Creative Director Jonathan Schoenberg has joined its Advisory Board
For more information and to download any of these reports, visit https://www.83bar.com/market-feasibility.
About 83bar Inc.
83bar Inc. headquartered in Austin, Texas manages the patient journey from symptom to solution. We empower patients with education to help self-champion and expedite a positive healthcare outcome. Our 4-part LENA (Locate, Evaluate, Navigate & Activate) system delivers ready-to-act patients to medical providers, on behalf of our medical device, medical diagnostics, and medical sciences partners. Over the last 5 years, we have completed over 1.5 million prospective patient conversations resulting in 100,000+ successful patient pathway outcomes across 20+ therapeutic areas and associated diseases. To find out how 83bar can help your medical device, medical diagnostic, or clinical trial, visit us at www.83bar.com.
Source: 83bar Inc.
0 Comments
Latest on Amzeal News
- Construction Technology Startup Mosaic Hires Real Estate Veteran as First CFO
- First look: Clark Nexsen completes engineering building at NC State University
- Orchestry Announces Partnership with Softchoice to Make Work Simple in Microsoft 365
- Barcoding, Inc. Announces Partnership with Ignition by TELUS and Exceedra by TELUS
- New vertical screen gaming machine models increase attraction
- ACEINNA Names Michael DiGangi as Executive VP
- 2021 Marketing Excellence Awards—Call for Entries: Honoring the Best in B2B Services and Solutions Marketing
- edjuster Launches Fully Interactive Digital Contents Claims Portal
- Senseeker Engineering Acquires SE-IR Corporation
- VIZGARD Joins NVIDIA's Accelerator for AI Start-ups
- eMoney Advisor Veterans Start Firm to Help Fintech CEOs Jump Start Growth
- ChartSpan Names Keith Lynn, Chief Technology Officer
- Wink, Link and Meet for a Drink! The Newest Meet Now App has Arrived!
- Florida small town festival ranks Top 50 BEST in nation
- Ordyx POS Brings Exciting New Features With Launch of OrdyxOne, Their Latest Software Update
- Delray Beach Branding Agency Celebrates Women in Business on International Women's Day
- Field Force Tracker Enhances Contract Management for Fire Control and Security Monitoring Companies
- Digital Cash Processing, Genmega Partner to Deliver Next Generation ATM Functionality
- Nationally Syndicated Radio Show "Radio Bassment" Launching Daily Programming 7 Days a Week
- AKCP Adds RADIUS Authentication Protocols to SP2+ and SPx+